LONDON: Drugmakers including Mylan NV and Lupin Ltd are considering bids for Bayer AG’s dermatology business as the German company sells assets ahead of its US$66bil acquisition of Monsanto Co.
Leo Pharma A/S, Cadila Healthcare Ltd. and Torrent Pharmaceuticals Ltd are also weighing offers, the people said, asking not to be identified because the deliberations are private. Non-binding bids for Bayer’s dermatology unit, which could fetch more than 1 billion euros (US$1.1bil), may be due as soon as this week, the people said.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
